<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30030557</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>25</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>25</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-0851</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>67</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer immunology, immunotherapy : CII</Title>                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>            </Journal>            <ArticleTitle>Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing.</ArticleTitle>            <Pagination>                <MedlinePgn>1437-1447</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-018-2206-0</ELocationID>            <Abstract>                <AbstractText>The construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = D-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds monovalent Tn antigen as noted by ELISA, FACS, and glycan array technologies. Kt-IgM-8 demonstrated in vitro and in vivo tumor killing against the Michigan Cancer Foundation breast cell line 7 (MCF-7). In vitro tumor killing was observed using an LDH assay that measured antibody-induced complement-dependent cytotoxicity and these results were validated in an in vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model. Kt-IgM-8 is effective in killing tumor cells at 30% cytotoxicity, and furthermore, it demonstrated approximately 40% reduction in tumor growth in the MCF-7 model.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Trabbic</LastName>                    <ForeName>Kevin R</ForeName>                    <Initials>KR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kleski</LastName>                    <ForeName>Kristopher A</ForeName>                    <Initials>KA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Mengchao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bourgault</LastName>                    <ForeName>Jean-Paul</ForeName>                    <Initials>JP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Prendergast</LastName>                    <ForeName>Jillian M</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Siamab Therapeutics, Inc., Newton, MA, 02458, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dransfield</LastName>                    <ForeName>Daniel T</ForeName>                    <Initials>DT</Initials>                    <AffiliationInfo>                        <Affiliation>Siamab Therapeutics, Inc., Newton, MA, 02458, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andreana</LastName>                    <ForeName>Peter R</ForeName>                    <Initials>PR</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5300-6700</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA. peter.andreana@utoledo.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 CA156661</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R43 CA186326</GrantID>                    <Agency>National Cancer Institute (US)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>N261200700063C</GrantID>                    <Agency>U.S. Department of Health and Human Services</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>N261200900034C</GrantID>                    <Agency>U.S. Department of Health and Human Services</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Cancer Immunol Immunother</MedlineTA>            <NlmUniqueID>8605732</NlmUniqueID>            <ISSNLinking>0340-7004</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015295">Antigens, Tumor-Associated, Carbohydrate</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000922">Immunotoxins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C040286">Tn antigen</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015295" MajorTopicYN="N">Antigens, Tumor-Associated, Carbohydrate</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000922" MajorTopicYN="N">Immunotoxins</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Complement-dependent cytotoxicity</Keyword>            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>            <Keyword MajorTopicYN="N">Monoclonal antibody</Keyword>            <Keyword MajorTopicYN="N">Thomsen-nouveau</Keyword>            <Keyword MajorTopicYN="N">Tumor-associated carbohydrate antigens</Keyword>            <Keyword MajorTopicYN="N">Xenograft</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>02</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30030557</ArticleId>            <ArticleId IdType="doi">10.1007/s00262-018-2206-0</ArticleId>            <ArticleId IdType="pii">10.1007/s00262-018-2206-0</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>